Q1 2024 Earnings Estimate for Immunocore Holdings plc (NASDAQ:IMCR) Issued By Leerink Partnrs

Immunocore Holdings plc (NASDAQ:IMCR) – Leerink Partnrs issued their Q1 2024 EPS estimates for Immunocore in a research note issued to investors on Monday, April 29th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($0.49) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.54) per share. Leerink Partnrs also issued estimates for Immunocore’s Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.58) EPS and FY2025 earnings at ($2.14) EPS.

Several other equities research analysts also recently weighed in on IMCR. Canaccord Genuity Group upped their price objective on shares of Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a report on Thursday, February 29th. Guggenheim reaffirmed a “buy” rating and issued a $92.00 price objective on shares of Immunocore in a report on Tuesday, April 23rd. SVB Leerink assumed coverage on shares of Immunocore in a report on Monday. They issued an “outperform” rating and a $74.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Immunocore in a report on Wednesday, March 6th. Finally, Mizuho upped their price target on shares of Immunocore from $86.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Immunocore currently has a consensus rating of “Moderate Buy” and an average price target of $80.92.

Immunocore Stock Performance

IMCR stock opened at $59.46 on Thursday. The company has a market capitalization of $2.96 billion, a P/E ratio of -51.26 and a beta of 0.92. The company has a 50-day simple moving average of $61.68 and a 200 day simple moving average of $60.94. Immunocore has a fifty-two week low of $42.21 and a fifty-two week high of $76.98. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.12). Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The firm had revenue of $70.16 million for the quarter, compared to analyst estimates of $53.25 million. During the same period last year, the firm posted ($0.63) EPS. The business’s revenue was up 22.4% compared to the same quarter last year.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Immunocore by 103.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after purchasing an additional 426 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock valued at $181,000 after buying an additional 674 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Immunocore by 1.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company’s stock valued at $5,639,000 after buying an additional 1,513 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of Immunocore by 26.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock valued at $389,000 after buying an additional 1,572 shares in the last quarter. Finally, Trexquant Investment LP grew its stake in shares of Immunocore by 6.5% in the 4th quarter. Trexquant Investment LP now owns 28,545 shares of the company’s stock valued at $1,950,000 after buying an additional 1,746 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.